Programa de doctorat: Doctorat en Polímers i Biopolímer

Fernández González, Pol

Garriga Solé, Pere

Morillo Cazorla, Margarita

Wang, Feifei

English

UPCommons. Portal del coneixement obert de la UPC

Rhodopsin is the key retinal protein in vision Mutations in the rhodopsin gene cause retinal degenerative diseases such as retinitis pigmentosa (RP).RhodopsinLight sensing at theretinaFormation of visual imageSignal processingPhototransductionLight is converted into an electrical signal0103What is RP?Treatment for RPRP (Retinitis pigmentosa) is a genetic disorder,mainly caused by rhodopsin mutations thateventually leads to blindness in affected people.RP affects 1 in every 5000 people worldwide, makingRP the most common inherited visual disease[3].02 Symptoms of RPPrevalence of RPThere is no standard treatment for RP patients.Current research aims at developing approaches thatcan delay the retinal degenerative process[4].Our goal is to find novel ligands that cancompensate the mutations and act as therapeuticagents for RP [5].Our experimental approachSearch for new allosteric ligandsas modulators of rhodopsin activity for the treatment of RPEffects of different allosteric modulators.[6]➢ Biochemical and biophysical analysis of the purified rhodopsin mutants➢ Expression of mutant rhodopsins in cell cultures and in transgenic miceMolecular Biotechnology research at GBMI (GaiaBuilding), focuses on the structure-function relationshipsof membrane proteins, specifically G protein-coupledreceptors. The primary research interest lies inunderstanding the molecular basis of diseases associatedwith mutations in these receptors, particularly retinaldegenerative diseases caused by mutations in thephotoreceptor protein rhodopsin [1]. The goal of thisresearch is to develop novel molecular approaches for thetreatment of blinding diseases such as retinitispigmentosa (RP).The background of our researchThe direction of our researchNovel ligands for the treatment of retinal degenerative diseasesFeifei Wang, Pol Fernandez-Gonzalez, Margarita Morillo and Pere GarrigaDepartament d’Enginyeria Quimica, Grup de Biotecnologia Molecular i Industrial (GBMI), Centre de Biotecnologia Molecular (CEBIM), Universitat Politecnica de Catalunya, Edifici Gaia, Rambla Sant Nebridi 22, 08222 Terrassa, Catalonia, Spain. E-mail: feifei.wang@upc.edu➢ Screening of novel ligands thatcan stabilize the rhodopsin mutantsThe signaling pathway of rhodopsin in rods and rod bipolar cells[2]UV-vis absorption spectrum of purified rhodopsin (Rho) from bovine retinasSpectrum[1]Razzaghi N. Effect of Sodium Valproate on the Conformational Stability of the Visual G Protein-Coupled Receptor Rhodopsin. Molecules. 202;26(10):3032. [2] Lenahan C. Rhodopsin: A Potential Biomarker for Neurodegenerative Diseases. Front Neurosci. 2020;14:326. [3] O'Neal TB, Luther EE. Retinitis Pigmentosa. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2023. [4] Cross N. Current and Future Treatment of Retinitis Pigmentosa. Clin Ophthalmol. 2022 Aug 31;16:2909-2921.[5]Herrera-Hernández MG. Flavonoid allosteric modulation of mutated visual rhodopsin associated with retinitis pigmentosa. Sci Rep. 2017;7(1):11167. [6] Lenahan C. Rhodopsin: A Potential Biomarker for Neurodegenerative Diseases. Front Neurosci. 2020;14:326. References

Novel ligands for the treatment of retinal degenerative diseases

https://upcommons.upc.edu/bitstream/2117/388091/1/poster_Feifei%20Wang.pdf

Novel ligands for the treatment of retinal degenerative diseases

Abstract

Similar works

Full text

Available Versions

UPCommons. Portal del coneixement obert de la UPC